INADEQUACY OF CHLORPROGUANIL 20 mg PER WEEK AS CHEMOPROPHYLAXIS FOR FALCIPARUM MALARIA IN KENYA
Identifieur interne : 003293 ( Main/Exploration ); précédent : 003292; suivant : 003294INADEQUACY OF CHLORPROGUANIL 20 mg PER WEEK AS CHEMOPROPHYLAXIS FOR FALCIPARUM MALARIA IN KENYA
Auteurs : W. M. Watkins [États-Unis] ; A. J. Oloo [États-Unis] ; H. M. Gilles [États-Unis] ; A. D. Brandling-Bennett [États-Unis] ; R. E. Howells [États-Unis] ; D. K. Koech [États-Unis]Source :
- The Lancet [ 0140-6736 ] ; 1987.
English descriptors
- Teeft :
- Active metabolite, Antimalarial activity, Attack rate, Blood cells, Cape verde islands, Causal prophylaxis, Cerebrospinal fluid, Chemoprophylactic agent, Chlorcycloguanil, Chloroquine, Chlorproguanil, Chlorproguanil recipients, Chronic carrier, Claude bernard, Claude bernard hospital, Clin nutr, Clinical status, Coronary heart disease, Dietary carbohydrate, Dihydrofolate, Dihydrofolate reductase inhibitors, Drug administration, Drug levels, East africa, Falciparum, Falciparum infections, Falciparum malaria, Growth rate, High density lipoprotein cholesterol, High density lipoproteins, Immunosorbent assay, Inhibitor, Kenya, Kenya coast, Lipoprotein, Maladies infectieuses, Malaria, Metabolic aspects, Nutr, Parasite, Placebo, Placebo administration, Placebo group, Placebo recipients, Plasma levels, Plasma lipids, Plasmodium, Plasmodium falciparum, Proguanil, Prophylaxis, Prophylaxis study, Pyrimethamine, Reductase, Research institute, Resistant parasites, Second half, Serological studies, Suppressive prophylaxis, Virus type, Watkins, Weekly adult dose, Weekly dose, Wellcome trust, Wellcome trust research laboratories.
Abstract
Abstract: After treatment with chloroquine and pyrimethamine/sulfadoxine, 118 school children aged 6 to 10 years living near the Kenyan coast were enrolled in a malaria chemoprophylaxis study and followed up for 20 weeks. Children were randomly assigned to receive either chlorproguanil 20 mg weekly (n = 78) or placebo (n = 37). The attack rate of Plasmodium falciparum infection was 42% in chlorproguanil recipients (39·8 episodes per 1000 person-weeks of prophylaxis) and 73% in placebo recipients (69·2 episodes per 1000 person-weeks, p <0·02). Sensitivity tests on 36 isolates successfully cultured in vitro showed that all 21 isolates from chlorproguanil recipients were resistant to dihydrofolate-reductase inhibitors, whereas only. 3 of 15 isolates from the placebo group were resistant (p < 10-6). Chlorproguanil in a weekly adult dose of 40 mg does not provide adequate prophylaxis against P falciparum in Kenya, probably because drug levels between doses fall below those required to suppress parasites resistant to dihydrofolate-reductase inhibitors.
Url:
DOI: 10.1016/S0140-6736(87)91966-0
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000D75
- to stream Istex, to step Curation: 000D75
- to stream Istex, to step Checkpoint: 002052
- to stream Main, to step Merge: 003365
- to stream Main, to step Curation: 003293
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>INADEQUACY OF CHLORPROGUANIL 20 mg PER WEEK AS CHEMOPROPHYLAXIS FOR FALCIPARUM MALARIA IN KENYA</title><author><name sortKey="Watkins, W M" sort="Watkins, W M" uniqKey="Watkins W" first="W. M." last="Watkins">W. M. Watkins</name></author><author><name sortKey="Oloo, A J" sort="Oloo, A J" uniqKey="Oloo A" first="A. J." last="Oloo">A. J. Oloo</name></author><author><name sortKey="Gilles, H M" sort="Gilles, H M" uniqKey="Gilles H" first="H. M." last="Gilles">H. M. Gilles</name></author><author><name sortKey="Brandling Bennett, A D" sort="Brandling Bennett, A D" uniqKey="Brandling Bennett A" first="A. D." last="Brandling-Bennett">A. D. Brandling-Bennett</name></author><author><name sortKey="Howells, R E" sort="Howells, R E" uniqKey="Howells R" first="R. E." last="Howells">R. E. Howells</name></author><author><name sortKey="Koech, D K" sort="Koech, D K" uniqKey="Koech D" first="D. K." last="Koech">D. K. Koech</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:471B4B767E9457544F25FB3732D7AA544B0CD2D9</idno><date when="1987" year="1987">1987</date><idno type="doi">10.1016/S0140-6736(87)91966-0</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-5MGVCFTB-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000D75</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D75</idno><idno type="wicri:Area/Istex/Curation">000D75</idno><idno type="wicri:Area/Istex/Checkpoint">002052</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002052</idno><idno type="wicri:doubleKey">0140-6736:1987:Watkins W:inadequacy:of:chlorproguanil</idno><idno type="wicri:Area/Main/Merge">003365</idno><idno type="wicri:Area/Main/Curation">003293</idno><idno type="wicri:Area/Main/Exploration">003293</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">INADEQUACY OF CHLORPROGUANIL 20 mg PER WEEK AS CHEMOPROPHYLAXIS FOR FALCIPARUM MALARIA IN KENYA</title><author><name sortKey="Watkins, W M" sort="Watkins, W M" uniqKey="Watkins W" first="W. M." last="Watkins">W. M. Watkins</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biomedical Sciences Research Centre and Clinical Research Centre, Kenya Medical Research Institute, Nairobi, KenyaWellcome Trust Research Laboratories, Nairobi, KenyaLiverpool School of Tropical Medicine, Liverpool, UKCenters for Disease Control, US Public Health Service, Department of Health and Human Services, Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Oloo, A J" sort="Oloo, A J" uniqKey="Oloo A" first="A. J." last="Oloo">A. J. Oloo</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biomedical Sciences Research Centre and Clinical Research Centre, Kenya Medical Research Institute, Nairobi, KenyaWellcome Trust Research Laboratories, Nairobi, KenyaLiverpool School of Tropical Medicine, Liverpool, UKCenters for Disease Control, US Public Health Service, Department of Health and Human Services, Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Gilles, H M" sort="Gilles, H M" uniqKey="Gilles H" first="H. M." last="Gilles">H. M. Gilles</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biomedical Sciences Research Centre and Clinical Research Centre, Kenya Medical Research Institute, Nairobi, KenyaWellcome Trust Research Laboratories, Nairobi, KenyaLiverpool School of Tropical Medicine, Liverpool, UKCenters for Disease Control, US Public Health Service, Department of Health and Human Services, Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Brandling Bennett, A D" sort="Brandling Bennett, A D" uniqKey="Brandling Bennett A" first="A. D." last="Brandling-Bennett">A. D. Brandling-Bennett</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biomedical Sciences Research Centre and Clinical Research Centre, Kenya Medical Research Institute, Nairobi, KenyaWellcome Trust Research Laboratories, Nairobi, KenyaLiverpool School of Tropical Medicine, Liverpool, UKCenters for Disease Control, US Public Health Service, Department of Health and Human Services, Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Howells, R E" sort="Howells, R E" uniqKey="Howells R" first="R. E." last="Howells">R. E. Howells</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biomedical Sciences Research Centre and Clinical Research Centre, Kenya Medical Research Institute, Nairobi, KenyaWellcome Trust Research Laboratories, Nairobi, KenyaLiverpool School of Tropical Medicine, Liverpool, UKCenters for Disease Control, US Public Health Service, Department of Health and Human Services, Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Koech, D K" sort="Koech, D K" uniqKey="Koech D" first="D. K." last="Koech">D. K. Koech</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biomedical Sciences Research Centre and Clinical Research Centre, Kenya Medical Research Institute, Nairobi, KenyaWellcome Trust Research Laboratories, Nairobi, KenyaLiverpool School of Tropical Medicine, Liverpool, UKCenters for Disease Control, US Public Health Service, Department of Health and Human Services, Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">The Lancet</title><title level="j" type="abbrev">LANCET</title><idno type="ISSN">0140-6736</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1987">1987</date><biblScope unit="volume">329</biblScope><biblScope unit="issue">8525</biblScope><biblScope unit="page" from="125">125</biblScope><biblScope unit="page" to="128">128</biblScope></imprint><idno type="ISSN">0140-6736</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0140-6736</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active metabolite</term><term>Antimalarial activity</term><term>Attack rate</term><term>Blood cells</term><term>Cape verde islands</term><term>Causal prophylaxis</term><term>Cerebrospinal fluid</term><term>Chemoprophylactic agent</term><term>Chlorcycloguanil</term><term>Chloroquine</term><term>Chlorproguanil</term><term>Chlorproguanil recipients</term><term>Chronic carrier</term><term>Claude bernard</term><term>Claude bernard hospital</term><term>Clin nutr</term><term>Clinical status</term><term>Coronary heart disease</term><term>Dietary carbohydrate</term><term>Dihydrofolate</term><term>Dihydrofolate reductase inhibitors</term><term>Drug administration</term><term>Drug levels</term><term>East africa</term><term>Falciparum</term><term>Falciparum infections</term><term>Falciparum malaria</term><term>Growth rate</term><term>High density lipoprotein cholesterol</term><term>High density lipoproteins</term><term>Immunosorbent assay</term><term>Inhibitor</term><term>Kenya</term><term>Kenya coast</term><term>Lipoprotein</term><term>Maladies infectieuses</term><term>Malaria</term><term>Metabolic aspects</term><term>Nutr</term><term>Parasite</term><term>Placebo</term><term>Placebo administration</term><term>Placebo group</term><term>Placebo recipients</term><term>Plasma levels</term><term>Plasma lipids</term><term>Plasmodium</term><term>Plasmodium falciparum</term><term>Proguanil</term><term>Prophylaxis</term><term>Prophylaxis study</term><term>Pyrimethamine</term><term>Reductase</term><term>Research institute</term><term>Resistant parasites</term><term>Second half</term><term>Serological studies</term><term>Suppressive prophylaxis</term><term>Virus type</term><term>Watkins</term><term>Weekly adult dose</term><term>Weekly dose</term><term>Wellcome trust</term><term>Wellcome trust research laboratories</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: After treatment with chloroquine and pyrimethamine/sulfadoxine, 118 school children aged 6 to 10 years living near the Kenyan coast were enrolled in a malaria chemoprophylaxis study and followed up for 20 weeks. Children were randomly assigned to receive either chlorproguanil 20 mg weekly (n = 78) or placebo (n = 37). The attack rate of Plasmodium falciparum infection was 42% in chlorproguanil recipients (39·8 episodes per 1000 person-weeks of prophylaxis) and 73% in placebo recipients (69·2 episodes per 1000 person-weeks, p <0·02). Sensitivity tests on 36 isolates successfully cultured in vitro showed that all 21 isolates from chlorproguanil recipients were resistant to dihydrofolate-reductase inhibitors, whereas only. 3 of 15 isolates from the placebo group were resistant (p < 10-6). Chlorproguanil in a weekly adult dose of 40 mg does not provide adequate prophylaxis against P falciparum in Kenya, probably because drug levels between doses fall below those required to suppress parasites resistant to dihydrofolate-reductase inhibitors.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Géorgie (États-Unis)</li></region></list><tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Watkins, W M" sort="Watkins, W M" uniqKey="Watkins W" first="W. M." last="Watkins">W. M. Watkins</name></region><name sortKey="Brandling Bennett, A D" sort="Brandling Bennett, A D" uniqKey="Brandling Bennett A" first="A. D." last="Brandling-Bennett">A. D. Brandling-Bennett</name><name sortKey="Gilles, H M" sort="Gilles, H M" uniqKey="Gilles H" first="H. M." last="Gilles">H. M. Gilles</name><name sortKey="Howells, R E" sort="Howells, R E" uniqKey="Howells R" first="R. E." last="Howells">R. E. Howells</name><name sortKey="Koech, D K" sort="Koech, D K" uniqKey="Koech D" first="D. K." last="Koech">D. K. Koech</name><name sortKey="Oloo, A J" sort="Oloo, A J" uniqKey="Oloo A" first="A. J." last="Oloo">A. J. Oloo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003293 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003293 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:471B4B767E9457544F25FB3732D7AA544B0CD2D9
|texte= INADEQUACY OF CHLORPROGUANIL 20 mg PER WEEK AS CHEMOPROPHYLAXIS FOR FALCIPARUM MALARIA IN KENYA
}}
| This area was generated with Dilib version V0.6.33. |  |